Anti-NGF Antibody and Antigen-Binding Fragment Patent Grant
Summary
USPTO granted Patent US12595298B2 to XIYUAN ANJIAN MEDICINE (SHANGHAI) CO., LTD. for an anti-NGF antibody and its antigen-binding fragment, covering the preparation method and therapeutic applications for NGF-mediated diseases. The patent includes 6 claims and was filed on August 2, 2021.
What changed
USPTO issued Patent US12595298B2 granting XIYUAN ANJIAN MEDICINE (SHANGHAI) CO., LTD. exclusive rights to an anti-NGF antibody composition, its antigen-binding fragment, and associated polynucleotides and vectors. The patent covers methods of preparation and therapeutic applications for treating NGF-mediated diseases and disorders.
For pharmaceutical and biotechnology companies developing nerve growth factor (NGF) targeting therapies, this patent establishes intellectual property barriers requiring careful freedom-to-operate analysis. Competitors pursuing similar anti-NGF antibody programs should evaluate potential licensing needs or design-around strategies. Research institutions and drug developers working in the pain management or neurodegenerative disease space should monitor this portfolio for competitive implications.
What to do next
- Monitor patent portfolio for freedom-to-operate implications
- Assess potential licensing opportunities for NGF antibody therapeutics
- Review patent claims for R&D collaboration possibilities
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Anti-NGF antibody and antigen-binding fragment thereof, preparation method, and application thereof
Grant US12595298B2 Kind: B2 Apr 07, 2026
Assignee
XIYUAN ANJIAN MEDICINE (SHANGHAI) CO., LTD
Inventors
Xiaohui Yuan, Guoyong Wang, Yujiao Liu, Donghong Zheng
Abstract
Provided are an anti-NGF antibody or an antigen-binding fragment thereof, a preparation method and an application thereof. Also provided is an isolated polynucleotide encoding the anti-NGF antibody or the antigen-binding fragment thereof, as well as a vector containing the isolated polynucleotide. Also provided is use of the antibody or the antigen-binding fragment thereof of the present invention in preparing the medicament for the treatment of NGF-mediated diseases or disorders.
CPC Classifications
C07K 16/22 C07K 16/46 C12N 15/13 C12N 15/63 C12N 5/00 A61K 39/395
Filing Date
2021-08-02
Application No.
17906190
Claims
6
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.